NCT01488838View on ClinicalTrials.gov

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Malignant Salivary Gland Tumors
Interventions
DRUG

Cisplatin: 40 mg/m2 weekly during radiation

Cisplatin: 40 mg/m2 weekly during radiation for 7 doses

RADIATION

Radiation: 60-66 Gy in 2 Gy daily fractions

Radiation: 60-66 Gy in 2 Gy daily fractions

Trial Locations (1)

11211

King Faisal Specialist Hospital& Research Center, Riyadh

All Listed Sponsors
collaborator

Radiation Therapy Oncology Group

NETWORK

lead

King Faisal Specialist Hospital & Research Center

OTHER

NCT01488838 - A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | Biotech Hunter | Biotech Hunter